Early Alzheimer's Disease: Developing Drugs for Treatment; Draft Guidance for Industry; Availability

Primary source

Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.

Published

March 18, 2024

Issuing agencies

Health and Human Services DepartmentFood and Drug Administration

Full Text

<html>
<head>
<title>Federal Register, Volume 89 Issue 53 (Monday, March 18, 2024)</title>
</head>
<body><pre>
[Federal Register Volume 89, Number 53 (Monday, March 18, 2024)]
[Notices]
[Page 19329]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: C1-2024-05178]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2013-D-0077]


Early Alzheimer's Disease: Developing Drugs for Treatment; Draft 
Guidance for Industry; Availability

Correction

    In notice document 2024-05178, appearing on pages 17850 through 
17851 in the issue of Tuesday, March 12, 2024, make the following 
correction:
    On page 17850, in the second column, on the third line, ``May 13, 
2024'' should read ``June 10, 2024''.

[FR Doc. C1-2024-05178 Filed 3-15-24; 8:45 am]
BILLING CODE 0099-10-D


</pre></body>
</html>

View on FederalRegister.gov →Plain-text source

Indexed from Federal Register on March 18, 2024.

This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.